Ozempic Side Effects: Complete FDA Safety Guide
Ozempic (semaglutide) is FDA-approved for type 2 diabetes and cardiovascular risk reduction. The most common side effects are gastrointestinal, nausea, vomiting, diarrhoea, constipation, and abdominal pain, and the most serious are pancreatitis, gallbladder disease, kidney injury, hypoglycaemia with insulin, and a boxed warning about thyroid C-cell tumours.
Ozempic (Semaglutide) is approved as a Glucagon-like peptide-1 (GLP-1) receptor agonist. Most common side effects are gastrointestinal (nausea, vomiting, diarrhoea, constipation). Serious risks include pancreatitis, kidney injury, gallbladder disease and hypoglycaemia with insulin. It carries an FDA boxed warning for thyroid C-cell tumours.
Key Takeaways
- Ozempic carries a boxed warning for thyroid C-cell tumours, contraindicated if personal or family history of medullary thyroid carcinoma or MEN2.
- The most common side effects are gastrointestinal: nausea, vomiting, diarrhoea, constipation, abdominal pain. Usually worst during dose escalation.
- Serious risks listed on the label: pancreatitis, acute kidney injury, gallbladder disease, severe hypoglycaemia with insulin/sulfonylureas, diabetic retinopathy worsening, hypersensitivity reactions.
- Alcohol does not directly interact, but worsens GI symptoms and hypoglycaemia risk, read more.
- Tell your anaesthetist if you are on Ozempic before any procedure, delayed gastric emptying creates an aspiration risk.
- Check Ozempic against your full medication list with the Allmeds drug interaction checker.
What is Ozempic, and what is it used for?
Ozempic is a once-weekly injectable semaglutide approved for type 2 diabetes and cardiovascular risk reduction. Wegovy is the same molecule approved for chronic weight management.
| Property | Detail |
|---|---|
| Generic name | Semaglutide |
| Brand names | Ozempic (T2D), Wegovy (weight management), Rybelsus (oral) |
| Drug class | GLP-1 receptor agonist |
| FDA approval status | Approved, type 2 diabetes, cardiovascular risk reduction in T2D with CVD |
| Route | Subcutaneous injection, once weekly |
| Boxed warning | Thyroid C-cell tumours (animal data) |
| Common GI side effects | Nausea, vomiting, diarrhoea, constipation, abdominal pain |
| Major label warnings | Pancreatitis, kidney injury, gallbladder disease, hypoglycaemia with insulin, retinopathy |
What are the side effects of Ozempic?
The FDA prescribing information for Ozempic groups side effects into common gastrointestinal symptoms (very frequent at initiation and dose escalation) and serious warnings (less frequent but clinically important). The table below summarises the labelled categories with severity colour-coding.
| Side Effect Category | What May Occur | Why It Matters |
|---|---|---|
| Pancreatitis | Severe, persistent abdominal pain (sometimes radiating to the back), nausea, vomiting | All GLP-1 labels warn about acute pancreatitis. Stop the medicine and seek urgent assessment. |
| Thyroid C-cell tumours (boxed warning) | Neck mass, hoarseness, difficulty swallowing, persistent neck pain | Animal studies show medullary thyroid carcinoma risk. Contraindicated if personal or family history of MTC or MEN2. |
| Acute kidney injury | Reduced urine output, swelling, fatigue, usually after vomiting or diarrhoea | Dehydration from GI side effects can precipitate AKI, particularly in patients with prior renal disease. |
| Severe hypoglycaemia | Sweating, shakiness, confusion, palpitations, seizure, loss of consciousness | Risk rises sharply when combined with insulin or sulfonylureas. Dose reduction of the other glucose-lowering drug is usually required. |
| Gallbladder disease | Right-upper abdominal pain, fever, jaundice | Cholelithiasis and cholecystitis are reported, especially with rapid weight loss. |
| Severe gastrointestinal reactions | Persistent nausea, vomiting, diarrhoea, constipation, abdominal pain | Common and dose-dependent. Most pronounced during initiation and dose escalation. |
| Diabetic retinopathy worsening | Blurred vision, vision changes | Rapid glucose lowering has been associated with transient worsening, relevant in long-standing type 2 diabetes. |
| Hypersensitivity reactions | Rash, urticaria, angioedema, anaphylaxis | Stop the medicine and seek urgent care for serious allergic features. |
| Injection-site reactions | Redness, swelling, itching, induration at the injection site | Usually mild; persistent reactions warrant clinical review. |
| Aspiration risk during anaesthesia | Delayed gastric emptying may leave food in the stomach during sedation | Disclose GLP-1 use to your anaesthetist before any procedure or surgery. |
Taking Ozempic alongside other medications?
Check Ozempic against your full medication list instantly. Allmeds scans the widest drug interaction database in minutes.
How does Ozempic work, and why does that drive the side effects?
Semaglutide mimics the natural GLP-1 hormone, it stimulates glucose-dependent insulin release, suppresses glucagon, slows gastric emptying, and reduces appetite. These same mechanisms drive the side-effect profile: slowed gastric emptying causes nausea and reflux, glucose-dependent insulin release amplifies hypoglycaemia risk when combined with insulin or sulfonylureas, and weight loss can precipitate gallstones.
Can you drink alcohol while taking Ozempic?
Alcohol is not a direct contraindication, but it worsens nausea, dehydration, and hypoglycaemia risk if you are also on insulin or sulfonylureas.
Symptoms and when to seek care
Seek urgent medical assessment if you experience any of the following while taking Ozempic:
- Severe, persistent abdominal pain (possible pancreatitis)
- Sudden swelling of the face, lips, tongue or throat, or difficulty breathing (allergic reaction)
- Right-upper abdominal pain with fever or jaundice (gallbladder disease)
- Severe vomiting or diarrhoea with reduced urine output (dehydration / kidney injury)
- Severe hypoglycaemia, sweating, confusion, palpitations, loss of consciousness (especially if also on insulin or sulfonylurea)
- New neck mass, hoarseness, or difficulty swallowing (thyroid concern)
- New or worsening depression, mood changes, or suicidal thoughts (Wegovy/Zepbound)
Common Questions About Ozempic Side Effects
Nausea, vomiting, diarrhoea, constipation, and abdominal pain, usually worst during the first few weeks of treatment or after a dose increase. Most settle as the body adapts. Persistent or severe symptoms warrant clinical review.
Ozempic has been studied in multi-year trials in type 2 diabetes. Long-term tolerability is broadly acceptable, but the boxed warning about thyroid C-cell tumours and the risks of pancreatitis, gallbladder disease, and kidney injury remain. Ongoing monitoring is essential.
Ozempic carries an FDA boxed warning for thyroid C-cell tumours, based on rodent studies showing medullary thyroid carcinoma. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).
Acute kidney injury has been reported, usually in patients who become dehydrated from vomiting or diarrhoea. Maintain hydration, particularly during dose escalation, and tell your doctor if you have pre-existing kidney disease.
Yes. Ozempic slows gastric emptying, which can leave food in the stomach during sedation or general anaesthesia and increase aspiration risk. Many anaesthetic services now ask patients to pause GLP-1 medicines before elective procedures, discuss this with your prescriber and anaesthetist.
References
- U.S. Food & Drug Administration. Ozempic (semaglutide) prescribing information. fda.gov.
- U.S. Food & Drug Administration. Wegovy (semaglutide) prescribing information. fda.gov.
- U.S. Food & Drug Administration. Mounjaro (tirzepatide) prescribing information. fda.gov.
- U.S. Food & Drug Administration. Zepbound (tirzepatide) prescribing information. fda.gov.
- European Medicines Agency. Ozempic, Wegovy, Mounjaro, EPAR product information. ema.europa.eu.
- Therapeutic Goods Administration (Australia). Australian Register of Therapeutic Goods (ARTG). tga.gov.au.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216.
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.
Check Ozempic against your full medication list
Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile, in minutes.